Pre‐ and on‐treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non–small cell lung cancer

The survival outcomes of patients with advanced non–small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) are variable. This study investigated whether pre‐ and on‐treatment lactate dehydrogenase (LDH) could better prognosticate and select patients for ICI therapy.

[1]  M. Petrova,et al.  Neutrophil to lymphocyte ratio as a potential predictive marker for treatment with pembrolizumab as a second line treatment in patients with non-small cell lung cancer. , 2020, Bioscience trends.

[2]  Y. Hu,et al.  Pretreatment lactate dehydrogenase may predict outcome of advanced non small‐cell lung cancer patients treated with immune checkpoint inhibitors: A meta‐analysis , 2019, Cancer medicine.

[3]  P. V. Van Schil,et al.  Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  A. Tafreshi,et al.  Pembrolizumab plus Chemotherapy for Squamous Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[5]  J. Satagopan,et al.  LDH-A regulates the tumor microenvironment via HIF-signaling and modulates the immune response , 2018, PloS one.

[6]  Arun Ahuja,et al.  Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer , 2018, Cancer cell.

[7]  E. Felip,et al.  Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer , 2018, JAMA oncology.

[8]  Abhijit A. Patel,et al.  Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA , 2018, Clinical Cancer Research.

[9]  V. Gebski,et al.  Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis , 2017, JAMA oncology.

[10]  Yuki Kataoka,et al.  P1.07-004 Predictive Biomarkers of Response to Nivolumab in Non–Small Cell Lung Cancer: A Multicenter Retrospective Cohort Study , 2017 .

[11]  E. Felip,et al.  Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Hidekazu Suzuki,et al.  Predictive Factors for Poor Progression-free Survival in Patients with Non-small Cell Lung Cancer Treated with Nivolumab. , 2017, Anticancer research.

[13]  V. Servois,et al.  Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  J. Karp,et al.  Elevated lactate dehydrogenase (LDH) can be a marker of immune suppression in cancer: Interplay between hematologic and solid neoplastic clones and their microenvironments. , 2017, Cancer biomarkers : section A of Disease markers.

[15]  Carlos Barrios,et al.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial , 2017, The Lancet.

[16]  E. Felip,et al.  P3.02c-063 Lactate Dehydrogenase (LDH) as a Surrogate Biomarker to Checkpoint-Inhibitors for Patient with Advanced Non–Small-Cell Lung Cancer (NSCLC): Topic: IT Biomarkers , 2017 .

[17]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[18]  Keunchil Park,et al.  Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial , 2016, The Lancet.

[19]  S Senan,et al.  Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[21]  K. Ballman,et al.  Biomarker: Predictive or Prognostic? , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  L. Holmberg,et al.  Serum lactate dehydrogenase and survival following cancer diagnosis , 2015, British Journal of Cancer.

[23]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[24]  S. Barni,et al.  Prognostic role of lactate dehydrogenase in solid tumors: A systematic review and meta-analysis of 76 studies , 2015, Acta oncologica.

[25]  K. Silay,et al.  A Laboratory Prognostic Index Model for Patients with Advanced Non-Small Cell Lung Cancer , 2014, PloS one.

[26]  Z. Szallasi,et al.  Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma , 2014, Cancer Immunology, Immunotherapy.

[27]  Daniel J Sargent,et al.  Predictive biomarker validation in practice: lessons from real trials , 2010, Clinical trials.

[28]  M. Tsao,et al.  Molecular predictive and prognostic markers in non-small-cell lung cancer. , 2009, The Lancet. Oncology.